PURPOSE: We used (18)F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec). METHODS: The pilot study included nine patients with progressive AF receiving oral treatment with imatinib at a daily dose of 800 mg. Patients were examined using PET prior to the start of therapy and during imatinib treatment. Restaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) was performed in parallel using CT and/or MRI and served as reference. RESULTS: The clinical outcomes in nine evaluable patients were as follows: seven patients with stable disease, and two patients with progressive disease. A 27% decrease in the median average standardized uptake value (SUV) of the sequential PET examinations was demonstrated in all evaluable patients with three patients (33%) showing a decrease in SUV of more than 40% (48%, 52% and 54%, respectively); no patient showed a substantial increase in SUV. CONCLUSION: To our knowledge, this is the first series of AF patients undergoing treatment with imatinib and monitored using sequential PET imaging, that allows detection of SUV changes after imatinib induction, thus helping to decide whether treatment should be continued or not.
PURPOSE: We used (18)F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec). METHODS: The pilot study included nine patients with progressive AF receiving oral treatment with imatinib at a daily dose of 800 mg. Patients were examined using PET prior to the start of therapy and during imatinib treatment. Restaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) was performed in parallel using CT and/or MRI and served as reference. RESULTS: The clinical outcomes in nine evaluable patients were as follows: seven patients with stable disease, and two patients with progressive disease. A 27% decrease in the median average standardized uptake value (SUV) of the sequential PET examinations was demonstrated in all evaluable patients with three patients (33%) showing a decrease in SUV of more than 40% (48%, 52% and 54%, respectively); no patient showed a substantial increase in SUV. CONCLUSION: To our knowledge, this is the first series of AFpatients undergoing treatment with imatinib and monitored using sequential PET imaging, that allows detection of SUV changes after imatinib induction, thus helping to decide whether treatment should be continued or not.
Authors: G Pignatti; G Barbanti-Bròdano; D Ferrari; F Gherlinzoni; F Bertoni; P Bacchini; E Barbieri; A Giunti; M Campanacci Journal: Clin Orthop Relat Res Date: 2000-06 Impact factor: 4.176
Authors: M Schulte; D Brecht-Krauss; B Heymer; A Guhlmann; E Hartwig; M R Sarkar; C G Diederichs; M Schultheiss; J Kotzerke; S N Reske Journal: Eur J Nucl Med Date: 1999-06
Authors: Scott M Schuetze; Brian P Rubin; Cheryl Vernon; Douglas S Hawkins; James D Bruckner; Ernest U Conrad; Janet F Eary Journal: Cancer Date: 2005-01-15 Impact factor: 6.860
Authors: Jae-Cheol Jo; Yong Sang Hong; Kyu-Pyo Kim; Jae-Lyun Lee; Jeeyun Lee; Young Suk Park; Sun Young Kim; Jin-Sook Ryu; Jong-Seok Lee; Tae Won Kim Journal: Invest New Drugs Date: 2014-01-16 Impact factor: 3.850
Authors: Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Lothar R Pilz; Ludwig G Strauss; Christos Sachpekidis; Peter Hohenberger Journal: Biomed Res Int Date: 2013-05-16 Impact factor: 3.411
Authors: Eric A Walker; Jonelle M Petscavage; Pamela L Brian; Chika Iloanusi Logie; Kenneth M Montini; Mark D Murphey Journal: Sarcoma Date: 2012-06-28